Without RCT data on semaglutide for the management of BAD, it is difficult to evaluate its safety and efficacy compared with other BAD therapeutics, but the abovementioned case underscores that newer, longer-acting, and more potent GLP-1RAs not necessarily provide better treatment results in BAD as compared with older, shorter-acting, and less potent GLP-1RAs such as liraglutide
Type V collagen controls the initiation of collagen fibril assembly
They also reported decreased hunger and increased feelings of fullness and satisfaction
I want to be careful here: I would not tell a patient that side effects mean the medication is working. Some people respond well with very minimal side effects
Data-sharing requests relating to data in this manuscript will be considered after the publication date and either (1) when this product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or (2) when clinical development discontinues and the data will not be submitted to regulatory authorities
Antoniades, C., Shirodaria, C., Warrick, N., Cai, S., Bono, J., Lee, J., Leeson, P., Neubauer, S., Ratnatunga, C., Pillai, R., Refsum, H
